Pandemic cases are still mounting. At the moment, there are 85.5 million cases around the world, with nearly 1.85 million unfortunate deaths. In the U.S., the case count is up to 20.7 million. In India, it’s up to 10.3 million. In Brazil, 7.7 million. In Russia, 3.22 million, and in the UK, cases are up to 2.72 million. While vaccines are being shipped, cases are still on the rise, increasing the need for vaccines and for pandemic testing. Making matters worse, a new strain of the virus has reportedly hit New York. In fact, according to NBC New York, a man in his 60s tested positive for the new strain that is reportedly 50% more contagious. Three other states have confirmed the new strain, as well, including Colorado, California, and Florida. With assistance needed with the pandemic, some of the top companies to keep an eye on include Datametrex AI Limited (TSXV:DM)(OTC:DTMXF), Pfizer Inc. (NYSE:PFE), Moderna Inc. (NASDAQ:MRNA), BioNTech (NASDAQ:BNTX), and Novavax Inc. (NASDAQ:NVAX).
Datametrex AI Limited (TSXV:DM)(OTC:DTMXF) BREAKING NEWS: Datametrex AI Limited is pleased to announce the Company has launched as of January 4, 2021 a Concierge Covid-19 testing service for the travelling public in both Toronto and Vancouver.
This concierge service is designed for individuals looking to be tested from the comfort of their own homes rather than using government locations and having to line up with crowds waiting to be tested at such locations. The Company’s sees an immediate need in the market to service people travelling to countries that require proof of a negative Covid-19 test prior to travel to or from Canada. This service will also be made available to individuals, groups, companies and other organizations that would like to have testing completed at a business location or on another site for personal or professional reasons. The idea of a concierge services originated from the work the Company is currently providing to the film industry where many of the high-profile actors requested to be tested in the comfort of their residence on an individual basis.
Testing or documentation for asymptomatic individuals is not being provided through the public health system at any government COVID-19 assessment centres. The Datametrex Covid-19 test is a standard nasal viral PCR lab test and can determine if you are currently infected with Covid-19. Results in 48 hours. You can book an appointment and use the pre-pay option through the Datametrex website.
"With many countries requiring a pre-departure negative COVID-19 test in order to travel, Datametrex is proud to be a part of the solution to safely and with confidence reopen travel destinations world-wide. We have provided companies and governments with thousands of PCR based testing over the last few months and believe that testing is one of the answers to protecting global citizens." said Marshall Gunter, the Company's Chief Executive Officer.
The Company is not making any express or implied claims that its product has the ability to eliminate, cure or contain the Covid-19 (or SARS-2 Coronavirus) at this time.
Other related developments from around the markets include:
Pfizer Inc. (NYSE:PFE) and BioNTech SE announced they will supply an additional 100 million doses of COMIRNATY®, the companies’ COVID-19 Vaccine, to the 27 European Union (EU) member states in 2021. This announcement is a result of the European Commission’s decision to exercise its option to purchase an additional 100 million doses under its Advanced Purchase Agreement signed on November 11, 2020. This agreement brings the total number of doses to be delivered to the EU to 300 million. “We remain committed to moving as quickly and safely as possible to bring this vaccine to more people in Europe, as the deadly virus continues to spread at an alarming rate,” said Albert Bourla, Chairman and Chief Executive Officer, Pfizer. “In partnership with the European Commission, member states and healthcare providers, we will be able to reach a total of 150 million Europeans across the continent.”
Moderna Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, provided a supply update for the Moderna COVID-19 Vaccine, increasing its base-case global production estimate from 500 to 600 million doses for 2021. Moderna said it is continuing to invest and add staff to build up to potentially 1 billion doses for 2021. The Company said it expects about 100 million doses to be available in the United States by the end of the first quarter of 2021, with 200 million doses total available by the end of the second quarter. Moderna reported that approximately 18 million doses have been supplied to the U.S. Government to date. The vaccine received Emergency Use Authorization from the U.S. Food and Drug Administration (FDA) on December 18, 2020 and Moderna began supplying to the government shortly thereafter. Additional vaccine doses have also been supplied to the Canadian government following authorization by Health Canada's Interim Order on December 23, 2020.
BioNTech (NASDAQ:BNTX) wants to express its thanks and gratitude not only to its employees but also to the many partners who have assisted the company in successfully developing a vaccine for COVID-19. BioNTech acknowledges that without the tireless effort from its’ employees and partners, who have played a pivotal role in this effort, it would not have been able to achieve this historic company milestone, a journey which only began in early 2020. Data from its Phase 3 study have demonstrated that the vaccine is well-tolerated and 95% effective in preventing COVID-19. The vaccine has already received conditional marketing authorizations as well as emergency use authorizations in more than 45 countries around the world, including the United States and the European Union. BioNTech’s employees have made a significant contribution to this initiative, working around the clock to harness the power of mRNA and apply it to this effort of fighting against the devastating pandemic. In addition, our partner companies and organizations have provided the company with research expertise, critical supply support, and valuable insights and assistance throughout the development and trial process. Without them, achieving this result only 11 months after the initiation of Project Lightspeed would not have been possible.
Novavax Inc. (NASDAQ:NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, announced initiation of PREVENT-19, its pivotal Phase 3 study in the United States and Mexico to evaluate the efficacy, safety and immunogenicity of NVX-CoV2373, the Company’s COVID-19 vaccine candidate. The trial builds on research from Phase 1/2 studies demonstrating that the vaccine provoked a robust immune response, generated highly neutralizing antibodies against the virus and was generally well-tolerated. “With the COVID-19 pandemic raging around the globe, this trial is a critical step in building the global portfolio of safe and effective vaccines to protect the world’s population,” said Stanley C. Erck, president and chief executive officer, Novavax. “We thank our colleagues and partners who continue to work with us to urgently advance our commercial-scale manufacturing processes, and we are grateful for the hard work and assistance from Operation Warp Speed, the U.S. FDA and the government of Mexico on this program.”
Legal Disclaimer / Except for the historical information presented herein, matters discussed in this article contains forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. Winning Media is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. For making specific investment decisions, readers should seek their own advice. Winning Media is only compensated for its services in the form of cash-based compensation. Pursuant to an agreement Winning Media has been paid three thousand five hundred dollars for advertising and marketing services for Datametrex AI Limited by a third party. We own ZERO shares of Datametrex AI Limited. Please click here for full disclaimer.
Contact Information:
2818047972
[email protected]
